Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Genome Therapeutics Corp. (NasdaqNM:GENE)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
100 Beaver Street
Waltham, MA 02453
Phone: (781) 398-2300
Fax: (781) 893-9535
Email: investors@genomecorp.com
Employees (last reported count): 176
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 19%
·Over the last 6 months:
 · 2 insider buys; 9,000  shares (0.2% of insider shares)
 · one insider sell; 493.0K shares
  (10.4% of insider shares)
·Institutional: 25% (31% of float)
(114 institutions)
·Net Inst. Selling: 789.0K shares (+15.82%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Genome Therapeutics Corp. is engaged in the commercialization of genomics-based drug discovery. Through the identification of genes and the characterization of the function of those genes, the Company is seeking to accelerate the discovery and development of products to treat and diagnose a number of diseases. The United States government has selected the Company to participate in a number of government sponsored gene discovery programs, including the Human Genome Project, and the Rat Genome Sequencing Program. The Company's depth of experience in the genomics field permits it to be a leader in creating industrial scale genomics tools for product development. Its tools include high-throughput sequencing, sequence finishing, bioinformatics, functional genomics, and assay development.
More from Market Guide: Expanded Business Description

Financial Summary
Genome Therapeutics Corporation is a genomics-based drug target discovery company focusing on the discovery and characterization of novel targets in pathogens that are responsible for many serious human diseases. For the 39 weeks ended 5/26/01, revenues fell 1% to $20.2 million. Net loss totalled $4.7 million, up from $1.1 million. Results reflect a reduction in contract research revenue and lower milestone payments, and higher costs related to the internal research programs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Robert Hennessey, 59
Chairman
$446K$14.7M
Stephen Rauscher, 47
Pres, CEO, Director
--  --  
Stephen Cohen
CFO, Sr. VP
--  --  
Christopher Kelly, 47
Sr. VP and Gen. Mang. -- Drug Rescue
222K2.2M
Richard Labaudiniere, Ph.D
Sr. VP, of R&D
--  --  
Dollar amounts are as of 31-Aug-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GENEAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$4.75 
Recent Price$7.65 
52-Week High
on 1-Sep-2000
$25.625
Beta1.77 
Daily Volume (3-month avg)666.0K
Daily Volume (10-day avg)220.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-68.9%
52-Week Change
relative to S&P500
-58.2%
Share-Related Items
Market Capitalization$173.4M
Shares Outstanding22.7M
Float18.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$3.15 
Earnings (ttm)-$0.29 
Earnings (mrq)-$0.11 
Sales (ttm)$1.19 
Cash (mrq*)$2.44 
Valuation Ratios
Price/Book (mrq*)2.43 
Price/EarningsN/A 
Price/Sales (ttm)6.45 
Income Statements
Sales (ttm)$26.3M
EBITDA (ttm*)-$4.19M
Income available to common (ttm)-$6.41M
Profitability
Profit Margin (ttm)-24.3%
Operating Margin (ttm)-38.0%
Fiscal Year
Fiscal Year EndsAug 31
Most recent quarter
(fully updated)
26-May-2001
Most recent quarter
(flash earnings)
31-May-2001
Management Effectiveness
Return on Assets (ttm)-7.84%
Return on Equity (ttm)-9.90%
Financial Strength
Current Ratio (mrq*)4.04 
Debt/Equity (mrq*)0.11 
Total Cash (mrq)$55.4M
Short Interest
As of 8-Aug-2001
Shares Short1.49M
Percent of Float8.1%
Shares Short
(Prior Month)
1.58M
Short Ratio6.86 
Daily Volume217.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-May-2001, except mrq*/ttm* items as of 26-May-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.